Assesment of Treatment Outcomes of Aquired Aplastic Anemia in Children : A Retrospective and Prospective Cohort

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07131878

Acronym

TTT

Enrollment

Registered

2025-08-20

Start date

2025-09-15

Completion date

2028-01-15

Last updated

2025-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aplastic Anaemia (AA)

Brief summary

The goal of this observational study is to to assess of treatment Outcomes of Aquired Aplastic Anemia in children

Detailed description

This study will be conducted to investigate the clinical outcomes, and treatment modalities of patients diagnosed with aquired aplastic anaemia at Assiut University children Hospital The main question it aims to answer is:

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

1 Years to 18 Years

Healthy volunteers

Inclusion criteria

* Children aged 1-18 years diagnosed with acquired aplastic anemia, as confirmed by bone marrow examination and fulfilling diagnostic criteria (e.g., bone marrow cellularity \<25% and at least two of the following: absolute neutrophil count \<500/μL, platelet count \<20,000/μL, absolute reticulocyte count \<60,000/μL)123. * The bone marrow biopsy should be compitable with diagnosis * Diagnosed and/or treated at Assiut University Children's Hospital between Agust 2023 and Augst 2026. * Patients with complete medical records, including diagnostic, laboratory, and treatment data

Exclusion criteria

* Patients with inherited bone marrow failure syndromes (e.g., Fanconi anemia, dyskeratosis congenita) as confirmed by genetic testing or family history21. * Patients with incomplete or missing essential data in their medical records. * Patients diagnosed outside the specified study period or managed primarily at other institutions. * Patinets with neoplastic or granulomatous disease involving the bone marrow, systemic lupus erythematosus, AIDS, hypersplenism or other conditions associated with pancytopenia such as myelodysplastic syndrome,and paroxysmal nocturnal hemoglobinuria. * Patients exposed to antineoplastic chemotherapy or radiotherapy were excluded

Design outcomes

Primary

Measure	Time frame
To evaluate the treatment outcomes of children diagnosed with aplastic anemia.	July 2023-July 2026

Secondary

Measure	Time frame
To assess response rates to various treatment modalities, including: oImmunosuppressive therapy (IST) oHematopoietic stem cell transplantation (HSCT) oSupportive care only	July 2023_July 2026

Contacts

Primary ContactMarwa M Abozaid, master

marwaabozaid39@gmail.com+201146679786

Outcome results